Gilead's Biktarvy Profile Rises As CHMP Backs Daily HIV Therapy
Executive Summary
Biktarvy's strength in battle against ViiV Healthcare's dolutegravir franchises is seen as a 'double-edged sword' for Gilead in HIV contest amid foreseen old drug 'cannibalization'.
You may also be interested in...
Amid Pharma ‘Landmarks’ Cipla Develops Tenofovir Prodrug
Cipla’s chair Dr Yusuf Hamied highlighted a series of ‘landmarks’ along the company’s journey at its recent annual general meeting and also indicated that the firm’s tenofovir prodrug, currently in early stage development, could potentially challenge TAF.
Yescarta One Of Few Gilead Bright Spots, And Now It Has A Competing CAR-T
Yescarta is off to a strong launch, but with US FDA approval of Novartis' Kymriah in a similar indication it now it has a competing CAR-T product with a similar label. Gilead's HCV business declined as expected, but the HIV franchise had a worse Q1 than anticipated.
Gilead's Biktarvy Set For EU Approval
A combination therapy – Gilead Science’s Biktarvy – a hybrid medicine and a generic can look forward to EU approval after getting the OK from the EMA’s drug evaluation committee last week.